The combo was first approved in 2023 for BRCA-mutated metastatic castration-resistant prostate cancer. (Johnson & Johnson) Johnson & Johnson's Akeega is opening new fronts in prostate cancer treatment ...
Prevalence of breast cancer across racial, socioeconomic, and regional groups in the US: Analysis of comorbidity distributions using the National Inpatient Sample Database in 2019-2020.
Incidence of myelodysplastic syndrome in patients treated with PARP inhibitors: A systematic review.
Investigating the role of immunosurveillance by macrophage in supporting therapeutic strategies using CD47 blockade in MDS. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results